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Transmission of mechanical force via cell junctions is an important component that molds cells into 
shapes consistent with proper organ function. Of particular interest are the cadherin transmembrane 
proteins, which play an essential role in connecting cell junctions to the intra-cellular cytoskeleton. 
Understanding how these biomechanical complexes orchestrate intrinsic and extrinsic forces is 
important for our understanding of the underlying mechanisms driving morphogenesis. We have 
previously identified the Amot protein family, which are scaffold proteins that integrate polarity, 
junctional, and cytoskeletal cues to modulate cellular shape in endothelial as well as epithelial cells. 
In this report, we show that AmotL1 is a novel partner of the N-cadherin protein complex. We studied 
the role of AmotL1 in normal retinal as well as tumor angiogenesis using inducible endothelial-specific 
knock-out mice. We show that AmotL1 is essential for normal establishment of vascular networks in 
the post-natal mouse retina as well as in a transgenic breast cancer model. The observed phenotypes 
were consistent with a non-autonomous pericyte defect. We show that AmotL1 forms a complex with 
N-cadherin present on both endothelial cells and pericytes. We propose that AmotL1 is an essential 
effector of the N-cadherin mediated endothelial/pericyte junctional complex.
The formation of blood vessels demands an intrinsic synchronization of cellular events such as migration, for-
mation of cellular contacts and establishment of cellular asymmetry. This is exemplified in vascular development 
by the highly coordinated formation of the axial vessels by the proliferation and migration of mesodermal pro-
genitor cells to the body midline1. The circulatory network is further expanded through sprouting of endothe-
lial cells that migrate and anastomose with neighboring sprouts. This process invokes the formation and the 
dynamics of cell-cell junctions, apical-basal polarity as well as the control of the cytoskeleton to modulate cell 
shape. Maturation of vessels also involves the reciprocal interaction between endothelial cells and pericytes which 
envelope the vascular tube.
An intriguing question in biology is how such clearly complicated signals are integrated to control blood 
vessel formation. Here, studies of the Angiomotin (Amot) scaffold protein family may provide some mechanistic 
insight. This protein family consists of three members Amot, AmotL1 and AmotL2 that localize to junctions and 
regulate cell growth and motility (Zheng et al. 2009)2. All three members share a N-terminal domain with PPXY 
protein interaction motifs, a coiled-coil domain and a C-terminal protein-binding motif. Several groups have 
shown that the Amot proteins associate to the Crb3 and Par3 apical polarity proteins via the PDZ binding motif3,4. 
The coiled-coil domain binds the tumor suppressor Merlin as well as the RICH1 GAP protein4,5. The N-terminal 
WW-binding motif binds the HIPPO effectors YAP1, MST2 and LATS2 and also mediates binding to the 
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junctional protein MAGI1b and actin6,7. The identification of the Amot binding partners suggests a role of these 
scaffolds to integrate essential morphogenic cues to control cell shape and proliferation of multicellular tissues.
We have previously shown by gene inactivation in zebrafish and mouse models, that the three members of the 
Amot protein family exert distinct roles during blood vessel development8,9. AmotL2 associates with VE-cadherin 
in order to connect the adhesion junction complex to the actin filaments thus establishing a mechanical connec-
tion between endothelial cells9. Using traction force microscopy, we also demonstrated that AmotL2 is essential to 
generate force in endothelial junctions. This may explain the lack of aortic expansion when genetically interfering 
with AmotL2 expression during zebrafish or mouse development. The pivotal role of Amot in physiological angi-
ogenesis was demonstrated by the fact that its inactivation results in inhibition of migration of inter-segmental 
vessels in zebrafish and also affects blood vessel development in causing death in utero8. Finally, recent data 
indicate that Amot, similarly to AmotL2, is also part of a junctional complex as it associates to CDH11 and may 
be involved in promoting migration in prostate cancer10. Less is known however regarding the role of AmotL1 
in the formation and maintenance of cell-cell contacts. Morpholino knock-down experiments suggest a per-
turbed adhesion of stalk cells of inter-segmental vessels and some overlap in function with Amot (at the level of 
tight junctions)8,11. In this report, we have used an endothelial-specific knock-out approach to analyze the role 
of AmotL1 in normal and pathological angiogenesis in mice. We identify AmotL1 as a novel component of the 
N-cadherin adhesion protein complexes and provide evidence that AmotL1 is essential for vascular remodeling 
during angiogenesis.
Results
In order to investigate the role of AmotL1 in the vascular endothelium and other tissues, we used a genetic 
deletion approach to silence gene expression in mouse. To inactivate AmotL1 in a cell-type specific fashion, we 
generated mice with loxP sites flanking exons 5 and 6 (Supplementary Figure 1a). The amotL1flox/flox mice were 
mated with Cdh5 (PAC)-CreERT2 transgenic mice (hereafter abbreviated as amotL1ec+/ec+)12. This model allows 
the efficient tamoxifen-inducible conditional recombinase expression in the endothelial cell lineage (recombined 
mice are abbreviated amotL1ec−/ec−). Tamoxifen-induced recombination was verified by genomic PCR analysis 
(Supplementary Figure 1b). The efficiency of tamoxifen injections in inducing recombination events was also ana-
lyzed in tumors from MMTV-Cre/amotl flox/flox/MMTV-PyMT mice by western blot (Supplementary Figure 1c).
We analyzed effects of inactivation of AmotL1 protein expression during post-natal vascularization of the 
mouse retina. The retinas of newborn mice are avascular but become vascularized in a very reproducible manner 
over the first 10 days after birth12. In order to detect AmotL1 protein expression we have previously developed 
immunoaffinity-purified antibodies that did not cross-react to any of the other family members11. Western blot 
analysis showed expression of both AmotL1 isoforms (p90 and p100) in developing as well as in adult retina 
(Supplementary Figure 1d). We also used whole mount immunostaining of mouse retinas of post-natal day 6 
to analyze AmotL1 expression. AmotL1 showed junctional localization in established vessels of the developing 
vascular network. No staining above background was detectable in endothelial cells of the front of the expanding 
vascular network (Fig. 1a).
We then analyzed effects of inactivation of AmotL1 protein expression during post-natal vascularization of 
the mouse retina. In amotL1 inactivation experiments, pups were injected with tamoxifen on P1-3 and retinas 
were harvested on P6. The developing vasculature was visualized by whole mount staining using isolectin B412. 
Overall, the density of the vessel network of the amotL1 deficient retinas was reduced and covered a smaller area 
of the retina (Fig. 1b,e). The vascular density and the number of branching points, evaluated using the Angiotools 
program13, were significantly lower in the periphery and center of the amotL1ec−/ec− retinas (Fig. 1c,d,f–i). In 
contrast inactivation of amotL1 in adult mice did not have any effect on vessel branching or density (Fig. 1j,k).
The reduced expansion of the vessel network in amotL1ec−/ec− animals suggested a defect in cell migration. 
Luminal endothelial cells convert into tip cells that direct vessel migration and contribute to the development 
of a multicellular stalk14. Our analysis of tip cells did not reveal any obvious defect in tip cell morphology 
(Supplementary Figure 2a). Furthermore, the number of filopodial extensions per tip cell was not significantly 
different (Supplementary Figure 2b). However, the total number of tip cells per length unit was lower in amot-
L1ec−/ec− mice, which perhaps could be ascribed to the lower vascular density (Supplementary Figure 2c).
Endothelial cells depend on other cell types such as microglia, astrocytes and pericytes, to be able to form a 
functional circulatory network14. Each cell type is engaged in distinct functions such as controlling anastomoses 
(microglia), guiding network branching (astrocytes) and vessel maturation (pericytes). We went on to analyze 
whether inactivation of amotL1 affected endothelia-interacting cells in a non-autonomous manner. Whole mount 
immunostaining of P6 amotL1ec−/ec− retinas, performed to visualize microglia and astrocytes did not reveal any 
striking difference (Supplementary Figure 2d,e). Immunostaining using the NG2 pericyte marker revealed that 
mutant blood vessels of amotL1ec−/ec− retinas were associated with pericytes (Fig. 2a). However, the pericytes 
showed a decreased area of coverage as the mural cells displayed a changed morphology in that they “bulged” out 
from the vessels (Fig. 2a,b).
We then assessed the role of AmotL1 in two tumor model systems, the transgenic model of breast cancer 
MMTV-PyMT and the Lewis Lung Carcinoma (LLC) transplanted tumor model. In the first model, the MMTV 
promoter drives the expression of the Polyoma Middle-T oncogene in the mouse mammary epithelium15 allow-
ing studies of progressive breast tumor development over a period of 6–14 weeks. The amotL1ec+/ec+ mice were 
crossed into the MMTV-PyMT background. Genetic deletion was induced by intraperitoneal tamoxifen injec-
tions at week 4. Analysis of the infiltrating blood vessels in the tumor area revealed a marked difference in mor-
phology between the control and AmotL1 deficient mice. amotL1ec−/ec− vessels were quite enlarged and dilated 
as shown by CD31 and Collagen IV immunofluorescent stainings (Fig. 3a and quantification in b). Analysis of 
normal adult retinal vessels from the same mice showed no vascular defects (Fig. 3c and Supplementary Figure 3). 
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Figure 1. Defects in vessel formation in post-natal retinas of amotL1ec−/ec− mice. (a) Whole-mount 
immunofluorescence (IF) staining of wild-type mouse retina at postnatal day 6 (P6). Blood vessels were visualized 
with isolectin B4 (IB4, in red) and AmotL1 using rabbit anti-AmotL1 polyclonal antibodies (in green). The upper 
panels display the central blood vessels network and the lower panels are derived from the front of the expanding 
vasculature. (b–d) Whole-mount IF staining of amotL1ec+/ec+ and amotL1ec−/ec− mouse retinas at post-natal day 6 
(P6). Blood vessels were visualized with IB4 lectin staining. (e) Radial vessel expansion was quantified by the ratio 
of vessel length divided by the length of the retina as measured from the optic nerve. (f,g) Bar diagrams show 
quantification of branch points at the vessel front or in the vessel network. (h,i) Bar diagrams show quantification 
of vascular densities at the vessel front or in the vessel network. (j,k) Quantification of branching points and 
vascular density in retinas from adult animals after genetic deletions was induced in the adult stage. **P < 0.005; 
***P < 0.001. Size bars are (a and d) 50 μ m. (b) 1 mm. (c) 100 μ m.
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A lower functionality of the tumor vessels was indicated by the longer lag time until tumors were detected in the 
amotL1ec−/ec− mice, whereas tamoxifen administration did not affect tumor progression per se (Fig. 3d).
The LLC tumor transplantation model has been extensively used to study tumor vasculature and the efficacy 
of angiogenesis inhibitors16. The LLC tumors grow rapidly and form highly vascularized lesions within 10 days 
after injection. It has been previously shown that most of the LLC tumor vessels are immature and may regress 
upon treatment with inhibitors of the VEGF signaling pathway17. Here we challenged LLC cells in control and 
amotL1flox/flox mice, as shown in Supplementary Figure 4a, and we assessed that most of the vessels are associated 
with pericytes (Supplementary Figure 4b). Similar to the transgenic MMTV-PyMT model, ablation of amotL1 in 
LLC tumor endothelium resulted in a significant increase in vessel diameter (Supplementary Figure 4c). However, 
the inhibition of LLC-derived tumors was not significant in amotL1ec−/ec− compared to controls (Supplementary 
Figure 4d).
These observations raised the question how ablation of AmotL1 in the endothelial compartment caused 
vessel enlargement as well as morphological changes in the adjacent pericytes. Endothelial cells and pericytes 
Figure 2. AmotL1 deficiency affects pericyte morphology and coverage of blood vessels. (a) Retinas from 
p6 were stained with IB4 (in red) and anti-NG2 antibodies (in green). Images on the right: magnification of the 
boxed area. (b) The ratio of NG2/IB4 overlap in amotL1ec+/ec+ and amotL1ec−/ec− retinas. **P < 0.005. Size bar, 
40 μ m.
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Figure 3. Ablation of amotL1 in the endothelial lineage in the mouse MMTV-PyMT breast cancer model. 
(a) Tumors derived from amotL1ec+/ec+ or amotL1ec−/ec− MMTV-PyMT mice were stained with antibodies 
against CD31 (green) or Collagen IV (red) in order to visualize vessel morphology. (b) Quantification of 
vessel diameter of breast tumors from amotL1ec+/ec+ or amotL1ec−/ec− mice. (c) Quantification of retinal vessel 
diameter from adult amotL1ec+/ec+ and amotL1ec−/ec− mice. (d) Analysis of breast tumor incidence in MMTV-
PyMT mice in amotL1ec+/ec+ or amotL1ec−/ec− background. Size bar, 25 μ m.
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are closely connected in mature blood vessels where they jointly produce the blood vessel basal membrane. 
The two distinct cell types communicate by paracrine signaling factors as well as direct physical contact in 
cell-cell adhesions mediated by N-cadherin. In our previous studies we have shown that AmotL2 is part of the 
VE-cadherin junctional complex and affects endothelial radial actin filaments and cell morphology in the aorta9. 
Co-immunoprecipitation analysis in mouse endothelial cells showed that VE-cadherin was primarily associated 
with AmotL2 and weakly with Amot or AmotL1 (Fig. 4a). Endothelial cells also express N-cadherin that is, in 
contrast to VE-cadherin, not endothelial specific as it is expressed in a number of mesenchymal cells such as 
pericytes18. N-cadherin is thought to participate in vessel stabilization by interacting with peri-endothelial cells 
during vessel formation and therefore a possible binding partner for AmotL1. However, no association could be 
detected between AmotL1 and N-cadherin in the co-immunoprecipitation analysis (Fig. 4a). Previous findings 
have shown that in vitro and in vivo N-cadherin junctional localization is controlled by VE-cadherin expression 
level19–21. In wild type (wt) endothelial cells in vitro, N-cadherin displays a diffuse localization on the cellular 
membrane whereas in VE-cadherin depleted cells N-cadherin is localized at adherent junctions22. It was pos-
sible that a homotypic interaction between N-cadherin in different cell types was required for the recruitment 
of AmotL1 to N-cadherin associated adhesion complexes. The co-immunoprecipitation analysis was repeated 
in VE-cadherin−/− and VE-cadherin+/+ endothelial cells with the result that AmotL1 was being pulled down 
in complex with N-cadherin only in the VE-cadherin−/− cell line (Fig. 4b,c, Supplementary Figure 5). Similar 
results were obtained in VE-cadherin siRNA depleted endothelial cells (Fig. 4d). Co-localization of AmotL1 and 
N-cadherin in cellular junctions was also detected in VE-cadherin−/− cells (Fig. 4e).
We also analyzed AmotL1 and N-cadherin expression in pericytes. In the developing retina, AmotL1 
could be detected in PDGFR-beta positive pericytes associated to IB4-postive retinal blood vessels (Fig. 5a). 
Immunofluorescent analysis showed overlap between AmotL1 and N-cadherin (Fig. 5b). Furthermore, AmotL1 
could be pulled down associated to N-cadherin in human pericytes (Fig. 5c). In conclusion, we show that AmotL1 
is a specific partner of N-cadherin in both endothelial cells and pericytes and our data provide evidence that 
this interaction is important for vascular network organization and proper endothelial/pericytes interaction 
(Fig. 5d,e).
Discussion
In this paper we provide insight regarding the role of the scaffold protein AmotL1 in normal and pathological 
angiogenesis. We show for the first time that AmotL1 is associated to the cellular adhesion molecule N-cadherin. 
This highlights the importance of Amot proteins as specific interactors of cellular adhesion proteins with distinct 
roles in controlling the cellular architecture of blood vessels during angiogenesis.
We provide evidence that AmotL1 is essential for the development of a proper vascular network during nor-
mal vascularization of the mouse retina. Our previous findings have shown that AmotL2 links the VE-cadherin 
and confers mechanical force via contractile actin filaments via cell-cell junctions. In contrast, AmotL1 does not 
associate to VE-cadherin and it is apparently not involved in the homotypic interactions of endothelial cells. 
In support of this notion, we could show that AmotL1 does not bind VE-cadherin and that knock-down of 
AmotL1 does not visibly affect actin filaments associated with VE-cadherin. In vitro, VE-cadherin mediates adhe-
sion between adjacent endothelial cells and is located at adherens junctions whereas N-cadherin has a diffusely 
dispersed distribution all over the outer membrane. It has previously been shown that VE-cadherin displaces 
N-cadherin from endothelial cell junctions and that reduction of VE-cadherin allows N-cadherin to form homo-
typic cell-cell interactions19. In this report, we could only find evidence of AmotL1 binding to N-cadherin in the 
absence of VE-cadherin. This suggests that the recruitment of AmotL1 is dependent on homotypic N-cadherin 
interactions in cell junctions. The VE-cadherin-dependent displacement of N-cadherin from endothelial cell con-
tacts allows binding to perivascular N-cadherin expressing cells in vivo. Indeed, multiple reports have shown that 
N-cadherin is required for endothelial-pericyte cross-talk. N-cadherin is typically expressed in cells of mesenchy-
mal origin including vascular mural cells such as pericytes and smooth muscle cells. A shared basal membrane 
separates mural cells and endothelial cells but these cells make direct contact through cavities in the basal mem-
brane. Several pieces of evidence suggest that N-cadherin is essential for this interaction between endothelial cells 
and pericytes. Ji-Hye Paik and coworkers have shown that blocking N-cadherin binding in in vitro co-cultures 
abrogated the interaction of endothelial cells and pericytes23. Similar results in vivo in chick brain suggested 
that N-cadherin is essential for the interaction of endothelial cells and pericytes and the resulting stabilization 
of blood vessels24. Furthermore, genetic inactivation of N-cadherin resulted in impaired pericyte coverage of 
endothelial sprouts in vitro25.
In our experiments, we observed a non-autonomous phenotype in the pericytes of the developing mouse 
retina. As N-cadherin and AmotL1 are expressed in both endothelial cells and pericytes, it is compelling to spec-
ulate that ablation of AmotL1 in the endothelial compartment will affect the pericytes in a non-autonomous way. 
Indeed, in amotL1ec−/ec− retinas, the pericyte coverage was decreased as the pericytes changed shape and bulged 
out from the vessels.
Extensive data show that endothelial-derived PDGF-B is essential for the recruitment of pericytes in newly 
formed vessels26. Impaired access to PDGF-B through genetic manipulation alters the retinal vascular density 
and increases tumor blood vessel diameter27. This is quite similar to what we have observed in AmotL1 deficiency 
in endothelial cells during normal and tumor blood vessels development. AmotL1, however, appeared not to 
be essential for pericyte recruitment as there were no apparent change in the number of pericytes/vessels in the 
amotl1 ec/ec mice.
TGF-β has long been implicated in the maturation of blood vessels by stimulation of basal membrane compo-
nents28. Recently, Li and coworkers showed that inactivation of the TGF-beta effector protein smad4 in the central 
nervous system affected the pericytes-endothelial coupling of brain vessels. Interestingly, Smad4 together with 
Notch signaling affected the expression of N-cadherin. Cerebral capillaries with decreased levels of N-cadherin 
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Figure 4. AmotL1 is recruited to N-cadherin associated adhesion complexes in the absence of VE-cadherin. 
(a) Co-immunoprecipitation was performed using antibodies against Amot, AmotL1 and AmotL2 in MS-1 cells. 
AmotL2 was shown to be associated with VE-cadherin whereas AmotL1 could not be immunoprecipitated with 
VE-cadherin or N-cadherin. (b) Western blot analysis of junctional protein expression in VE-cadherin+/+, +/− and 
−/− endothelial cells (c) Co-immunoprecipitation of N-cadherin with AmotL1 in VE-cadherin−/− endothelial cells. 
(d) Immunoprecipitation analysis of endothelial cells siRNA depleted of VE-cadherin (e) Immunofluorescent 
staining of AmotL1 (in green) and N-cadherin (in red) in VE+/+ and VE−/− cells showing co-localization in cellular 
adhesion junctions in VE-cadherin deficient endothelial cells. Nuclei were visualized by DAPI staining (in blue). 
Size bar, 10 μ m.
www.nature.com/scientificreports/
8Scientific RepoRts | 6:30622 | DOI: 10.1038/srep30622
Figure 5. AmotL1 is expressed in pericyte and interacts with N-cadherin. (a) IF staining of AmotL1 (in green) 
in wild type mouse retina at P6. Endothelium was stained by IB4 (in purple) and pericytes were staining by 
PDGFR-beta (in red). AmotL1 is present in pericyte/endothelial junctions shown by co-localization of AmotL1 
and PDGFR-beta (green and purple staining, white arrow). Scale bar, 25 μ m. (b) Human vascular brain 
pericytes (HBVP) were stained by AmotL1 and N-cadherin and DAPI (blue) as indicated in the figure. Bottom: 
magnification of the boxed area on the top. (c) Co-immunoprecipitation of N-cadherin with AmotL1 in HBVP. 
(d) Endothelial AmotL1 deficiency results in decreased pericyte coverage of blood vessels. (e) Hypothetical model 
of how the N-cadherin/AmotL1 protein complex relays mechanical force between endothelial cells and pericytes.
www.nature.com/scientificreports/
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could maintain the ability to recruit pericytes but failed to form proper adhesions resulting in pericytes detach-
ments29. We propose a model by which AmotL1 is recruited to N-cadherin localized to peg-sockets in order to 
mechanically couple endothelial cells to pericytes via formation of actin filaments the functionally integrating 
cell-cell junctions with actomyosin contractility. This would be similar to the mechanisms of action of AmotL2, 
which in complex with VE-cadherin exerts force between endothelial cells via para-cellular actin filaments. We 
hypothesize that both AmotL1 and AmotL2 functionally integrate mechanical signals via distinct adhesion mol-
ecules to modulate vascular morphogenesis.
These findings raise the question whether AmotL1 is a crucial mediator of other cellular processes. 
Epithelial-mesenchymal transition involves the downregulation of E-cadherin and upregulation of N-cadherin. 
Expression of N-cadherin on the tumor cells surface facilitates the adhesion to endothelial cells and subsequently 
extravasation and metastasis30. Indeed, a recent study has shown that AmotL1 is upregulated and promotes inva-
sion in breast cancer31. Further studies may shed light whether the tumor: endothelial interactions are dependent 
on mechanical forces relayed by AmotL1.
Materials and Methods
Animals. All animal studies were approved by the North Stockholm Animal Ethical Committee. All experi-
ments were carried out in accordance with the guidelines of the Swedish Board of Agriculture. amotL1floxed/foxed 
mice, which carry a loxP-flanked amotL1 gene, were crossed to Cdh5(PAC)CreERT2 and ROSA26-EYFP 
double transgenic mice in order to perform loss of function studies. The final mouse model was then crossed with 
mice overexpressing the Polyoma virus Middle T under control of the MMTV promoter (MMTV-PyMT) bred 
in the animal facility of the Molecular Biotechnology Center (Turin). All mice in this report were in C57BL/6 
background.
Cell culture. Lewis lung carcinoma (LLC) cells were cultured in DMEM medium (GIBCO, Grand Island, NY) 
supplemented with 10% FCS (GIBCO), 1% glutamine and 1% penicillin/streptomycin (P/S, Sigma-Aldrich). 
Ms-1 cells were cultured in RPMI-1640 medium (GIBCO) supplemented with 10% FCS, 1% glutamine and 1% 
P/S. VE+/+ and VE−/− cells were cultured culture medium MCDB131 (GIBCO) supplemented with 20% FCS, 
glutamine (2 mM, Sigma-Aldrich), 1% P/S, sodium pyruvate (1mM, Sigma-Aldrich), heparin (100 μ g/ml, from 
porcine intestinal mucosa; Sigma-Aldrich), and endothelial cell growth supplement (ECGS) (5 μ g/ml, made 
from calf brain, Sigma-Aldrich). The medium for human vascular brain pericytes (HBVP) was purchased from 
PromoCell (C-28040).
Western blot. Cells were lysed in the following buffer (50 mM Tris-HCL pH 7.6, 150 mM NaCl, 1 mM EDTA, 
1% Nonident P40), 1 x protease inhibitor (Roche, 04693159001). Lysates were prepared with SDS sample buffer 
(Novex, 1225644) containing 10% sample reducing agent (Novex, 1176192). Proteins were fractionated in a pol-
yacrylamide Bis-Tris 4–12% gradient precast gel (Novex, NP0322BOX). Afterwards, proteins were transferred to 
a nitrocellulose membrane (Whatman, 10401396). The membrane was blocked in 5% non-fat milk PBS and 0.1% 
Tween 20 and incubated with the primary antibody overnight at 4 °C. The membrane was thereafter incubated for 
1 hour at R.T. with an adequate horseradish peroxidase-conjugated secondary antibody. Labeled proteins were 
detected with chemiluminescence (ECL; Amersham, RPN2232).
Immunoprecipitation analysis. Cell lysates were prepared in the buffer (50 mM Tris-HCL pH 7.6, 150 mM 
NaCl, 1 mM EDTA, 1% Nonident P40, 1 x protease inhibitor (Roche, 04693159001)). Lysates were incubated 
with protein G sepharose beads (GE, 17-0618-01) for 1.5 hours at 4 °C as pre-cleaning. Afterwards antibodies 
against AmotL1 or control rabbit immunoglobulins added in the lysates overnight under rotation at 4 °C. Protein 
G sepharose beads were added for additional 2 hours. Beads were washed 5 times with lyses buffer and heated 
for 10 min at 95 °C in 2 x LDS sample buffer (Novex, 1225644) containing 10% sample reducing agent (Novex, 
1176192). The samples were fractionated by SDS PAGE and subsequently western blotted. Fractions of whole cell 
lysates were western blotted for evaluation of IP protein input level.
Retina angiogenesis assay. Mouse retina angiogenesis assay were performed as previously published12,32. 
In brief, tamoxifen (Sigma) was injected intraperitoneally into newborn pups at the dose of 50 μ g/pup/day from 
postnatal day P1 to P3. Eyes were dissected at P6 and fixed in 4% paraformaldehyde for whole mount immu-
nostaining. Branching and vessel density was analyzed using the Angiotools software (https://ccrod.cancer.gov/
confluence/display/ROB2/Quick+ Guide).
Immunofluorescence staining. Fixed mouse retinas were dissected out from eyeball under microscope. 
Retinas was permeabilized and blocked in PBS containing 0.3% Triton X-100 and 2% BSA at 4 °C overnight. 
Primary antibody in pblec buffer (1.0% Triton X-100 plus 0.1 M MgCl2, 0.1 M CaCl2, 0.01 M MnCl2 in PBS) was 
added to the retina and incubated at 4 °C overnight and subsequently incubated with the fluorescent-conjugated 
secondary antibody. Digital images were taken by Leica TCS SP5 confocal microscope. Primary antibodies used 
are as follows: Isolectin B4 (IB4, 1:50), iBA1 (WAKO, 1:500), GFAP (Invitrogen, 1:100), Collagen IV (Millipore, 
1:100), rabbit anti-NG2 (Millipore, 1:50), PECAM1 (BD biosciences, 1:100), goat anti-GFP (Abcam, 1:500).
Xenograft Tumor Model. Tamoxifen was injected intraperitoneally to wild-type as well as amotL1flox/flox  
male mice (≥ 8 mice per group) at age of 6-week-old (1 mg/mouse/day) for 5 days in a row. Approximately, 
0.5 × 106 LLC tumor cells were subcutaneously injected into the right flank of the mouse on the last day of tamox-
ifen injection. Tumor growth was palpated twice per week and tumor volumes were calculated according to 
the formula: 0.52 × length × width × width. One week before sacrifice, same dosage of tamoxifen was injected 
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intraperitoneally into the tumor bearing mice for 5 days. When tumors reached the diameter of 10 mm, mice were 
sacrificed and tumors were resected and analyzed by cryohistology.
siRNA transfection. For siRNA transfections cells were seeded the day before transfection on glass 
slides (BD Falcon Cultureslides BD Biosciences) coated with 1% BD Matrigel Basement Membrane Matrix 
(BD Biosciences) in growth medium without antibiotics. Just before transfection, growth medium was exchanged 
for OPTI-MEM I Reduced Serum Media (Invitrogen). Smartpool siGENOME siRNAs (Dharmacon/Thermo 
Scientific) against VE-cadherin siRNA from Dharmacon (SMARTpool: ON-TARGETplus Cdh5 siRNA, 
L-041968-01-0005) as well as Non-Targeting siRNA Pool #2 (D-001206-14) were transfected into the cells with 
Oligofectamine Transfection Reagent (Invitrogen) according to the manufacturers protocol. siRNAs were used at 
the final concentrations of 0.32M for both control and AmotL2 siRNAs. Four hours after transfection serum was 
added to a final concentration of 20%. Cells were allowed to grow for 72 hours prior to evaluation by immunoflu-
orescence staining or western blot.
Statistical analysis. Statistical analysis of in vivo results based on at least four animals and four images from 
each sample tissue. Comparisons between different groups were performed using the standard two-tailed Student 
t-test. A value of P < 0.05 was considered as statistically significant (*P < 0.05, **P < 0.01 and ***P < 0.001).
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